ERBB2 and cancer: To further test whether direct engagement between cancer cells and immune cells is necessary for trastuzumab to trigger HER2 downregulation, we employed a transwell co-culturing system that retained immune cells in the upper chamber without direct contact with cancer cells at the bottom of the culture system.